Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cara Therapeutics, Inc.    CARA

CARA THERAPEUTICS, INC.

(CARA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Cara Therapeutics : Announces Presentation at American Society of Nephrology Kidney Week 2020

10/22/2020 | 09:18am EST

STAMFORD - Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that results from its KALM-2 pivotal Phase 3 trial of KORSUVA (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) will be presented at the American Society of Nephrology (ASN) Kidney Week 2020 annual meeting, which is being held virtually from October 22-25, 2020.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Cara has successfully completed its Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with CKD and is currently conducting Phase 2 trials of Oral KORSUVA in atopic dermatitis and primary biliary cholangitis patients with moderate-to-severe pruritus.

The FDA has conditionally accepted KORSUVA as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Forward-looking Statements

Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the expected timing for the submission of the Company's NDA for KORSUVA Injection for CKD-aP, the Company's ability to commercialize KORSUVA Injection and the Company's potential future growth and success. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics' filings with the Securities and Exchange Commission, including the 'Risk Factors' section of the Company's most recent Quarterly Report on Form 10-Q and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:

Janhavi Mohite

Tel: 212-362-1200

Email: janhavi.mohite@SternIR.com

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about CARA THERAPEUTICS, INC.
11/11CARA THERAPEUTICS : to Present at Multiple Upcoming Investor Conferences
AQ
11/11Cara Therapeutics to Present at Multiple Upcoming Investor Conferences
GL
11/09CARA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
11/09CARA : 3Q Earnings Snapshot
AQ
11/09CARA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financi..
AQ
11/09CARA THERAPEUTICS : Reports Third Quarter 2020 Financial Results
AQ
11/09Cara Therapeutics Reports Third Quarter 2020 Financial Results
GL
11/02CARA THERAPEUTICS : to Announce Third Quarter 2020 Financial Results on November..
AQ
11/02Cara Therapeutics to Announce Third Quarter 2020 Financial Results on Novembe..
GL
10/27CARA THERAPEUTICS : SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milest..
PR
More news
Financials (USD)
Sales 2020 65,1 M - -
Net income 2020 -53,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -10,1x
Yield 2020 -
Capitalization 731 M 731 M -
Capi. / Sales 2020 11,2x
Capi. / Sales 2021 25,7x
Nbr of Employees 76
Free-Float 83,9%
Chart CARA THERAPEUTICS, INC.
Duration : Period :
Cara Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 32,63 $
Last Close Price 14,67 $
Spread / Highest target 173%
Spread / Average Target 122%
Spread / Lowest Target 22,7%
EPS Revisions
Managers
NameTitle
Derek T. Chalmers President, Chief Executive Officer & Director
Thomas Reilly Chief Financial & Accounting Officer
Frèdèrique Menzaghi Chief Scientific Officer, Senior VP-R&D
Joana Goncalves Chief Medical Officer
Martin A. Vogelbaum Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CARA THERAPEUTICS, INC.-8.94%731
MODERNA, INC.680.88%60 441
LONZA GROUP AG61.27%46 692
CELLTRION, INC.87.85%41 055
IQVIA HOLDINGS INC.9.37%32 400
SEAGEN INC.49.05%30 708